Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized crossover study of dapagliflozin, exenatide, and their combination for albuminuria reduction in type 2 diabetes
2017-004709-42Phase 3Active
- Sponsor
- Martini Ziekenhuis
- Start
- Mar 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Forxiga sequence, Bydureon sequence and Forxiga + Bydureon sequence (3 arms). Primary endpoint: Percentage change from baseline in albumin:creatinine ratio in first morning void urine. Started Mar 2018; status: active.
02
Drugs
dapagliflozinexenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-004709-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004709-42.